slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 66,061-66,090
Pages 3,679
Rows per page 30
Component
66,061-66,090 of 110,355
12
The slide uses a central human anatomy diagram to map specific cancer types to their respective mesothelin expression rates.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
15
The slide uses a process diagram to illustrate the dose escalation cohorts leading to the Recommended Phase 2 Dose (RP2D).TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
16
RP2D (Recommended Phase 2 Dose) is highlighted at DL 3.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
17
The table categorizes adverse events into Hematologic, On Target/On Tumor, On Target/Off Tumor, and Other, with a specific highlight on the RP2D (Recommended Phase 2 Dose) column.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
20
The slide presents Kaplan-Meier curves for Progression-Free Survival and Overall Survival alongside a comparative table of historical study data.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
21
Includes waterfall plot of target lesion changes and Kaplan-Meier plots for PFS and OS.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
24
Data shows patient-specific longitudinal tracking of transgene copies/µg gDNA.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
27
The chart displays individual patient responses, with multiple patients achieving significant tumor regression.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
28
The slide uses a numbered list format to categorize clinical trial improvements.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
29
Includes a futility analysis note for MPM arms and collaboration branding.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
30
The chart shows the breakdown of patient eligibility by MSLN expression levels (50%, 2+/3+ vs 50%, 1+ vs Not eligible).TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
31
The chart is a swimmer plot showing patient response over time, including redosing events and disease progression.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
33
The chart uses horizontal bars to represent the development stage of each program.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
06
The data highlights the mechanism of action of KIT inhibition (inactivation and depletion) supported by Phase 1b interim results.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Beat · ProblemLoop · Cost Of Inaction1 hit
07
The slide presents a summary of preclinical efficacy and safety data alongside a table demonstrating high selectivity against other kinases.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Beat · SolutionLoop · Cost Of Inaction1 hit
09
The chart displays multiple dose cohorts (200mg QD, 200mg BID, 400mg BID, 500mg QD FED) with error bars representing standard deviation.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
13
Includes two line charts: one normalized to baseline and one showing absolute values.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
14
The schematic illustrates a dose escalation study with three cohorts of 10 patients each, separated by safety review committee (SRC) checkpoints.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
15
The chart shows a pharmacokinetic (PK) profile comparing two formulations of THB001.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
16
The slide uses clinical data to justify a new indication for a drug candidate by highlighting the role of mast cells in asthma pathophysiology.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
17
The slide outlines a randomized, placebo-controlled trial structure with specific allergen challenge points.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
18
The slide uses a timeline diagram to show clinical phases and key events (trial initiation, regulatory submission, data readout) from 2H'22 to 2H'24.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
20
Includes a patient quote and clinical imagery to emphasize the severity of the condition.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Beat · Market SizeLoop · Cost Of Inaction1 hit
22
DART stands for developmental and reproductive toxicology.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Quick Win Big Bet1 hit
07
Data source: Kelley Blue Book 2022.TurnOnGreen | Investor Presentation Deck | 23 slides · TurnOnGreen
Pitch deck Investor relations Beat · Market Size1 hit
08
The chart uses a combination of bar (quarterly) and line (cumulative) data to demonstrate market acceleration.TurnOnGreen | Investor Presentation Deck | 23 slides · TurnOnGreen
Pitch deck Investor relations Beat · ProblemLoop · Why Now1 hit
09
Slide highlights California as a leader in EV adoption and policy, providing quantitative market data and state-level goals.TurnOnGreen | Investor Presentation Deck | 23 slides · TurnOnGreen
Pitch deck Investor relations Loop · Why Now1 hit
11
Uses asterisks to denote current vs future goals.TurnOnGreen | Investor Presentation Deck | 23 slides · TurnOnGreen
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
05
The slide uses a before-after comparison for five business metrics, highlighting performance changes in a difficult macro environment.UBS | Results Presentation Deck | 27 slides · UBS
Conference presentation Investor relations Beat · NeedLoop · Before After1 hit
06
The slide uses a series of circular callouts to highlight specific financial metrics for different business segments.UBS | Results Presentation Deck | 27 slides · UBS
Conference presentation Investor relations 1 hit